Roches risdiplam meets primary endpoint results in phase 3 trial
Category: #health  By Mateen Dalal  Date: 2019-11-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roches risdiplam meets primary endpoint results in phase 3 trial

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective treatment of this disease. 

Roche Holding AG is one such Swiss multinational healthcare company. Roche has reportedly announced that a phase 3 trial of risdiplam has met its primary endpoint. The clinical trial was carried out to evaluating risdiplam in patients that are suffering from type 2 or 3 SMA. 

Through the positive results of the phase 3 trial, Roche’s hopes of taping into a slice of the SMA market have been buoyed. 

The company’s phase 3 trial enrolled patients that are suffering from less serious types of the debilitating muscle wasting disease. The type 2 and type 3 forms of the disease are less serious forms of Spinal Muscular Atrophy. However, they could still result in respiratory infections, mobility problems, and death. 

Reportedly, to evaluate risdiplam, the company enrolled 180 patients that are suffering from type 2 or type 3 SMA in its phase 2/3 clinical trial’s second part and further randomized to obtain placebo or the splicing modifier SMN2 through oral administration. 

A year after the treatment, the company noticed a change that is statistically significant on the motor function scale of MFM-32, which allowed the trial to meet its primary endpoint. Roche is planning to share these results with regulators to bring risdiplam to market in several nations including the U.S. 

However, the company has not yet shared the data from the second portion of Phase 2/3 clinical trial, making it difficult to determine its probability of winning an approval. However, the promising results of the first part of the 2/3 clinical trial signal that risdiplam could give tough competition to existing drugs like Biogen’s Spinraza and Novartis’ Zolgensma.

Sources cite that the company is planning to share the data from a 2/3 clinical trial at an upcoming medical congress. Meanwhile, the Swiss Big Pharma is working to generate data through another trial that has enrolled patients who are suffering from type 1 SMA as well. 

If the data supports a 2020 approval for all three SAM types, the SMA community would get access to the company’s third drug within a span of approximately three years. Roche would then have to persuade patients that risdiplam is a better alternative than Novartis’ gene therapy based Zolgensma and Biogen’s antisense oligonucleotide Spinraza. 

 

Source credit - https://www.fiercebiotech.com/biotech/roche-s-challenger-for-sma-market-hits-goal-phase-3

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...